StockData
RMTINasdaqPharmaceutical PreparationsFiscal year ends December 31

ROCKWELL MEDICAL, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$7.49+0.06 (+0.81%)

Close on Oct 19, 2026

Market cap
$29.65M
P/E (TTM)
–
Dividend yield
–

Earnings

Next report expected Nov 11, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 13, 2026Before market open$17.80M$-0.34$-0.04
Q1 FY2026
Ended Mar 31, 2026
May 7, 2026Before market open$17.30M$-0.04$-0.01
Q4 FY2025
Ended Dec 31, 2025
Jan 20, 2026Before market open$18.60M––
Q3 FY2025
Ended Sep 30, 2025
Nov 12, 2025Before market open$15.90M––
Q2 FY2025
Ended Jun 30, 2025
Aug 14, 2025Before market open$16.10M$-0.05$-0.01
Q1 FY2025
Ended Mar 31, 2025
May 12, 2025Before market open$18.90M$-0.04$-0.01
Q4 FY2024
Ended Dec 31, 2024
Mar 20, 2025Before market open$24.70M$-0.02$0.04
Q3 FY2024
Ended Sep 30, 2024
Nov 12, 2024Before market open$28.30M$0.05$0.09
Q1 FY2024
Ended Mar 31, 2024
May 14, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Jan 8, 2024Before market open–––
Q3 FY2023
Ended Sep 30, 2023
Nov 14, 2023Before market open–––

Company guidance

Outlook given with results on Aug 13, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Adjusted EBITDAnon-GAAP2026 Annual Guidance$1.00M to $2.00MMaintained
Gross Margin2026 Annual Guidance18% to 22%Maintained
Net Sales2026 Annual Guidance$70.00M to $75.00MMaintained

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Rockwell Medical filed with the SEC